Lun - Ven 8:00 - 17:00
^ FDA seeks more tests on a female Viagra, by Matthew Perrone, The Detroit Free Press, page 2A Wednesday, 12 February 2014 "FDA: Female sex drive drug needs more research - CNN.com".
[17][18] Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown (although it might be caused by the competition with endogenous serotonin), flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. [4][19] Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. [17] Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor. [15] As such, flibanserin has been described as a norepinephrine–dopamine disinhibitor (NDDI). The proposed mechanism of action refers to the Kinsey dual control model of sexual response.
[21] Various neurotransmitters, sex steroids, and other hormones have important excitatory or inhibitory effects on the sexual response. Among neurotransmitters, excitatory activity is driven by dopamine and norepinephrine, while inhibitory activity is driven by serotonin. The balance between these systems is of significance for a normal sexual response. By modulating serotonin and dopamine activity in certain parts of the brain, flibanserin may improve the balance between these neurotransmitter systems in the regulation of sexual response. Flibanserin was originally developed as an antidepressant,[24][15] but was found to have pro-sexual effects and was later repurposed for the treatment of hypoactive sexual desire disorder.
In June 2010, a federal advisory panel to the US Food and Drug Administration (FDA) unanimously voted against recommending approval of flibanserin, citing an inadequate risk-benefit ratio. The committee acknowledged the validity of hypoactive sexual desire as a diagnosis, but expressed concern with the drug's side effects and insufficient evidence for efficacy, especially the drug's failure to show a statistically significant effect on the co-primary endpoint of sexual desire. [25] Ahead of the votes, Boehringer Ingelheim had mounted a publicity campaign to promote the controversial disorder of "hypoactive sexual desire". [26] In 2010, the FDA issued a Complete Response Letter, stating that the new drug application could not be approved in its current form. The letter cited several concerns, including the failure to demonstrate a statistical effect on the co-primary endpoint of sexual desire and overly restrictive entry criteria for the two phase III trials. Archived from the original on 1 August 2017. "Advisers To FDA Recommend Agency Approve Drug To Boost Female Libido".
| Region | Estimated Cost per Month | Generic Version Available |
|---|---|---|
| USA | $400 | No |
| EU | €350 | No |
| Australia | AUD 550 | No |
| India | Approx. $50 (generic) | Yes |
Archived from the original on 4 June 2015. ^ "Critics: Women's Sex Pill Approval Vote Driven By PR, Not Science".
| Country | Approval Status | Year |
|---|---|---|
| United States | Approved | 2015 |
| Canada | Approved | 2016 |
| European Union | Pending/Under review | N/A |
| Australia | Not approved | N/A |
Archived from the original on 4 March 2021.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 20mg | 30 + 4 Pills | 68.05€ 64.81€ | |
| Kamagra | 100mg | 84 + 6 Pills | 264.44€ 251.85€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Levitra Original | 20mg | 34 + 2 Pills | 188.51€ 179.53€ | |
| Priligy Generic Dapoxetine | 60mg | 60 + 8 Pills | 183.06€ 174.34€ | |
| Kamagra Effervescent Tablets | 100 mg | 84 + 7 Pills | 202.91€ 193.25€ | |
| Cialis Generic | 2.5mg | 10 Pills | 28.51€ 27.15€ | |
| Viagra Soft Tabs | 100mg | 30 + 4 Pills | 83.06€ 79.10€ | |
| Levitra Generic | 40mg | 360 + 10 Pills | 704.99€ 671.42€ | |
| Cialis Professional | 40mg | 30 Pills | 148.94€ 141.85€ | |
| Super Kamagra | 160 mg | 32 + 4 Pills | 218.25€ 207.86€ | |
| Cialis Generic | 40mg | 360 + 10 Pills | 477.87€ 455.11€ | |
| Viagra Oral Jelly | 100mg | 10 Sachets | 46.36€ 44.15€ |
"First drug to improve sexual desire in women approved in the United States".
Archived from the original on 13 February 2021. Archived from the original on 7 April 2021.
The FDA recommended performing a new phase III trial with less restrictive entry criteria. [27] In October 2010, Boehringer announced that it would discontinue its development of flibanserin in light of the FDA's decision. Sprout responded to the FDA's cited deficiencies and refiled the new drug application in 2013. The submission included data from a new phase III trial and several phase I drug-drug interaction studies. [27][29] The FDA again refused the application, citing an uncertain risk/benefit ratio.
In December 2013, a Formal Dispute Resolution was filed,[30] which contained the requirements of the FDA for further studies. These include two studies in healthy subjects to determine if flibanserin impairs their ability to drive, and to determine if it interferes with other biochemical pathways. The Agency agreed to call a new Advisory Committee meeting to consider whether the risk-benefit ratio of flibanserin was favorable after this additional data was obtained. In June 2015, the US FDA Advisory Committee, which includes the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM), recommended approval of the drug by 18–6, with the proviso that measures be taken to inform women of the drug's side effects. [33][34] On 18 August 2015, the FDA approved Addyi (flibanserin) for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties.
The approval specified that flibanserin should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects. As of August 2015, Sprout Pharmaceuticals had not yet made an application to bayer vardenafil the European Medicines Agency for a marketing authorization. Even the Score, a coalition of women's groups brought together by a Sprout consultant, actively campaigned for the approval of flibanserin. The campaign emphasized that several approved treatments for male sexual dysfunction exist, while no such treatment for women was available. [36] The group successfully obtained letters of support from the President of the National Organization for Women, the editor of the Journal of Sexual Medicine, and several members of Congress. Approves Addyi, a Libido Pill for Women".
"Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women".
Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. The dual control model: The role of sexual inhibition & excitation in sexual arousal and behavior In Janssen, E. (Ed). "Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study". "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant".
^ "18 June 2010 meeting of the FDA Advisory Committee for Reproductive Health Drugs" (PDF). Archived from the original (PDF) on 13 September 2016. ^ "Drug for sexual desire disorder opposed by panel". Archived from the original on 11 February 2021. ^ a b "Joint Meeting of fildena 200 mg the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee" (PDF). Archived from the original on 26 March 2021. Archived from the original on 18 November 2015. Archived from the original on 6 November 2015.
Other organizations supporting the approval of flibanserin included the National Council of Women's Organizations, the Black Women's Health Imperative, the Association of Reproductive Health Professionals, National Consumers League, and the American Sexual Health Association. The approval was opposed by the National Women's Health Network, the National Center for Health Research and Our Bodies Ourselves. [42] A representative of PharmedOut said "To approve this drug will set the worst kind of precedent—that companies that spend enough money can force the FDA to approve useless or dangerous drugs. "[43] An editorial in JAMA noted that, "Although flibanserin is not the first product to be supported by a consumer advocacy group in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA's regulation have been particularly noteworthy, as have the extent of advocacy efforts ranging from social media campaigns to letters from members of Congress". In August 2015, Valeant Pharmaceuticals and Sprout Pharmaceuticals announced that Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
The initial response since the 2015 introduction of flibanserin to the US market was slow with 227 prescriptions written during the first three weeks. [46] The slow response may be related to a number of factors: physicians require about 10 minutes of online training to get certified; the medication costs about US$400 per month;[47] and questions about the drug's efficacy and need. Archived from the original on 7 June 2022. Archived from the original on 20 October 2020. "Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)".
Archived sexual enhancement pills (PDF) from the original on 14 November 2022. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000:493–538. "Nothing Is Wrong With Your Sex Drive". Archived from the original on 15 July 2017. "Raleigh's Sprout Pharmaceuticals awaits FDA ruling on female libido drug".
Archived from the original (PDF) on 5 June 2015. Archived from the original on 15 October 2010. ^ "Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women". Archived from the original on 19 March 2025. Archived from the original on 10 August 2015. Archived from the original on 3 June 2019.
"'Faux-advocacy,' not science, prompted FDA panel's OK of 'low libido' drug for women, critics charge".
Archived from the original on 30 August 2015. "Evaluation of Flibanserin: Science and Advocacy at the FDA".
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités